As bi­va­lent boost­er up­take crawls, Pfiz­er and BioN­Tech start ear­ly-stage pan-vari­ant tri­al

Pfiz­er and BioN­Tech an­nounced Thurs­day morn­ing that they be­gan a Phase I tri­al of a new pan-vari­ant Covid vac­cine com­bined with their Omi­cron-spe­cif­ic boost­er, hope­ful­ly …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER